Zavante Therapeutics, Inc.
http://www.zavantetherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zavante Therapeutics, Inc.
Keeping Track: US FDA Receives Submissions Galore As Year Ends
A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.
Keeping Track: FDA Starts November With A Bang
The latest drug development news and highlights from our FDA Performance Tracker.
Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice